Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

45.84
+0.90002.00%
Post-market: 45.840.00000.00%17:19 EDT
Volume:381.03K
Turnover:17.55M
Market Cap:3.50B
PE:61.12
High:46.70
Open:45.00
Low:45.00
Close:44.94
52wk High:49.12
52wk Low:18.26
Shares:76.29M
Float Shares:35.24M
Volume Ratio:0.56
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7500
EPS(LYR):0.7500
ROE:11.73%
ROA:7.18%
PB:6.16
PE(LYR):61.12

Loading ...

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.
·
Nov 14, 2025

Kiniksa CFO Mark Ragosa Reports Sale of Common Shares

Reuters
·
Oct 31, 2025

Kiniksa Pharmaceuticals International Plc : Jefferies Raises Target Price to $58 From $54

THOMSON REUTERS
·
Oct 29, 2025

Stock Track | Kiniksa Pharmaceuticals Plummets 11.98% as Q3 Earnings Fall Short of Expectations

Stock Track
·
Oct 28, 2025

Kiniksa Pharmaceuticals International PLC reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Oct 28, 2025

Kiniksa Pharmaceuticals Showcases Growth in Recurrent Pericarditis Market and Advances Cardiovascular Drug Pipeline

Reuters
·
Oct 28, 2025

Stock Track | Kiniksa Pharmaceuticals Plunges 6.53% Pre-Market on Q3 Earnings Miss

Stock Track
·
Oct 28, 2025

Kiniksa Pharma raises ARCALYST's 2025 sales forecast

Reuters
·
Oct 28, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32

MT Newswires Live
·
Oct 28, 2025

Kiniksa Pharmaceuticals Q3 2025 EPS $0.23 Misses $0.26 Estimate, Sales $180.855M Beat $167.358M Estimate

Benzinga
·
Oct 28, 2025

BRIEF-Kiniksa Pharmaceuticals Q3 EPS USD 0.25

Reuters
·
Oct 28, 2025

Kiniksa Pharmaceuticals: on-Track for Phase 2 Date Dose-Focusing Portion of the Kpl-387 Phase 2/3 Recurrent Pericarditis Trial in H2 2026

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals Q3 Operating Expenses USD 156.834 Million

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International Plc Expects 2025 Arcalyst Net Product Revenue of Between $670 Million and $675 Million

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International Expects Its Current Operating Plan to Remain Cash Flow Positive on an Annual Basis

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International PLC expected to post earnings of 32 cents a share - Earnings Preview

Reuters
·
Oct 24, 2025

Kiniksa Pharmaceuticals Chairman and CEO Sanj K. Patel Reports Disposal of Common Shares

Reuters
·
Oct 23, 2025

Kiniksa Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 17, 2025

How FDA Orphan Drug Status for KPL-387 at Kiniksa (KNSA) Has Changed Its Investment Story

Simply Wall St.
·
Oct 17, 2025

Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387

Dow Jones
·
Oct 17, 2025